Sydney M Crago

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

Adverum Biotechnologies is known for its therapeutic candidate Ixo-vec, in development for the treatment of wet age-related macular degeneration (AMD)

Both business moves further align Topcon with a long-term strategy for promoting data-driven predictive healthcare

The professor from Wills Eye Hospital in Philadelphia, Pennsylvania, explained why it's time to retire the term "sterile" when addressing culture-negative endophthalmitis

Anat Loewenstein, MD, shared recent research findings which indicate home monitoring is appropriate for atypical and complex pathologies

Joel Schuman, MD, explore the latest advancements in glaucoma laser treatments, including innovative techniques like DSLT and the benefits of selective laser trabeculoplasty

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

Continued research shows that earlier treatment significantly enhances tissue preservation in patients with geographic atrophy, emphasizing the importance of timely intervention.

A study shows enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

Dr Borkar, a vitreoretinal surgeon at Duke University, spoke to the Eye Care Network about her American Academy of Ophthalmology (AAO) presentation

Dr Miere presented the ACTOR study, illuminating vascular remodeling in patients with neovascular AMD, and the HERMES study, investigating perfusion changes in central retinal vein occlusion

María Berrocal, MD, spoke about the Vit-Buckle Society (VBS), which has become a regular feature at the European Society of Retina Specialists annual meeting

The current staging system fails to fully capture the neurovascular unit's status, said Stela Vujosevic, Md, PhD, FEBO

The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).

Jeremiah Tao, MD, FACS, used his Egyptian Ophthalmological Society keynote to explore complex and costly challenges in oculofacial surgery

A 12-month follow-up indicated no dose limiting toxicity and no ocular or systemic adverse effects

João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

Phil Lai, MD, chief medical officer of Perfuse Therapeutics, said the company's goal is to pioneer disease-modifying treatment that targets an underlying pathology of ischemia

At the Retina World Congress, we spoke with Siegfried Priglinger, MD, about ensuring the best outcomes for preschool-aged patients

Williams joins Topcon Healthcare from Heidelberg Engineering, where she held multiple senior leadership roles.

Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

The initiative marks the second annual ROP Awareness week, running from 24 February to 2 March, 2025